<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39310686</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1333-9451</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Acta clinica Croatica</Title><ISOAbbreviation>Acta Clin Croat</ISOAbbreviation></Journal><ArticleTitle>STUDY HYPOTHESIS: AGE, GENDER, PRESENCE OF DIABETES MELLITUS OR HYPERTENSION, AND ANTI-HYPERTENSIVE DRUGS ARE INDEPENDENT RISK FACTORS FOR COVID-19 MORTALITY.</ArticleTitle><Pagination><StartPage>447</StartPage><EndPage>456</EndPage><MedlinePgn>447-456</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.20471/acc.2023.62.03.6</ELocationID><Abstract><AbstractText>We aimed to investigate the effects of comorbid diseases and antihypertensive drugs on the clinical outcome of hospitalized patients with COVID-19 infection. A total of 1045 patients whose data could be gathered and confirmed from both hospital files and Turkish National Health Network records were retrospectively screened, and 264 of 1045 patients were excluded because of having more than one comorbid disease. The study population consisted of a total of 781 patients, of which 482 had no comorbid disease, while the remaining 299 patients had only one comorbid disease. The mortality risk was 7.532 times higher in those over 65 years of age compared to cases younger than 30 years (OR: 7.532; 95% CI: 1.733-32.730); the risk of mortality in men was 2.131 times higher than in women (OR: 2.131; 95% CI: 1.230-3.693); and presence of diabetes mellitus (DM) increased mortality risk 2.784 times (OR: 2.784; 95% CI: 1.288-6.019). While hypertension was not found to be an independent risk factor for COVID-19 mortality, age, gender, and presence of DM were independent risk factors for COVID-19 mortality. There was no association between antihypertensive drugs and mortality. Accordingly, age (&gt;65 years), gender (male), and presence of DM were independent risk factors for COVID-19 mortality, whereas hypertension and use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and their combinations with other antihypertensive drugs were not risk factors for COVID-19 mortality.</AbstractText><CopyrightInformation>Sestre Milosrdnice University Hospital.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karandere</LastName><ForeName>Faruk</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Bakirkoy Dr. Sadi Konuk Education and Training Hospital, Department of Internal Medicine, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kocoglu</LastName><ForeName>Hakan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Bakirkoy Dr. Sadi Konuk Education and Training Hospital, Department of Internal Medicine, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korkusuz</LastName><ForeName>Ramazan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bakirkoy Dr. Sadi Konuk Education and Training Hospital, Department of Infectious Diseases, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erismis</LastName><ForeName>Betul</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Bakirkoy Dr. Sadi Konuk Education and Training Hospital, Department of Internal Medicine, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hursitoglu</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bakirkoy Dr. Sadi Konuk Education and Training Hospital, Department of Internal Medicine, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kart</LastName><ForeName>Kadriye Yasar</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Bakirkoy Dr. Sadi Konuk Education and Training Hospital, Department of Infectious Diseases, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Acta Clin Croat</MedlineTA><NlmUniqueID>9425483</NlmUniqueID><ISSNLinking>0353-9466</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="Y">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin II receptor blocker</Keyword><Keyword MajorTopicYN="N">Angiotensin-converting enzyme inhibitor</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39310686</ArticleId><ArticleId IdType="pmc">PMC11413996</ArticleId><ArticleId IdType="doi">10.20471/acc.2023.62.03.6</ArticleId><ArticleId IdType="pii">acc-62-447</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Coronavirus disease (COVID-19) situation reports. Retrieved from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ last accessed 13 June 2020.</Citation></Reference><Reference><Citation>Turkey Ministry of Health Daily Coronavirus Table. Retrieved from: https://covid19.saglik.gov.tr/last accessed: 13 June 2020 (in Turkish).</Citation></Reference><Reference><Citation>COVID-19 pandemic data. Retrieved from: https://en.wikipedia.org/wiki/Template:COVID-19_pandemic_data last accessed 13 June 2020.</Citation></Reference><Reference><Citation>Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049–57. 10.18632/aging.103000</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103000</ArticleId><ArticleId IdType="pmc">PMC7185114</ArticleId><ArticleId IdType="pubmed">32267833</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. 10.1016/S0140-6736(20)30211-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. [Epub ahead of print]10.1001/jama.2020.1585</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JJ, Dong X, Cao YY, Yuan Y, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75:1730–41. 10.1111/all.14238</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14238</ArticleId><ArticleId IdType="pubmed">32077115</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. China Medical Treatment Expert Group for COVID-19 comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020. May;55(5):2000547. 10.1183/13993003.00547-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00547-2020</ArticleId><ArticleId IdType="pmc">PMC7098485</ArticleId><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolomatov S, Zukow W, Novikov N, Markaryan A, Eremeeva E. Expression of the renin-angiotensin system components in oncologic diseases. Acta Clin Croat. 2019;58(2):354–64. 10.20471/acc.2019.58.02.21</Citation><ArticleIdList><ArticleId IdType="doi">10.20471/acc.2019.58.02.21</ArticleId><ArticleId IdType="pmc">PMC6884393</ArticleId><ArticleId IdType="pubmed">31819334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020. March;579(7798):265–9. 10.1038/s41586-020-2008-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–10. 10.1161/CIRCULATIONAHA.104.510461</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.104.510461</ArticleId><ArticleId IdType="pubmed">15897343</ArticleId></ArticleIdList></Reference><Reference><Citation>Giavina-Bianchi P, Aun MV, Agondi RC, Kalil J. Debate on drugs that may aggravate COVID-19. J Allergy Clin Immunol Pract. 2020;8(7):2452–3. 10.1016/j.jaip.2020.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2020.04.037</ArticleId><ArticleId IdType="pmc">PMC7195066</ArticleId><ArticleId IdType="pubmed">32344190</ArticleId></ArticleIdList></Reference><Reference><Citation>Republic of Turkey Ministry of Health. COVID-19 (SARS-CoV-2 Infection) Guide – Science Board Study. Available at: https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf?type=file. Accessed 05/07/2020.</Citation></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42. 10.1001/jama.2020.2648</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. 10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–8. 10.1007/s00134-020-05991-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5. 10.1016/j.ijid.2020.03.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.03.017</ArticleId><ArticleId IdType="pmc">PMC7194638</ArticleId><ArticleId IdType="pubmed">32173574</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiva Sisnieguez CE, Espeche WG, Salazar MR. Arterial hypertension and the risk of severity and mortality of COVID-19. Eur Respir J. 2020. June 11;55(6):2001148. 10.1183/13993003.01148-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01148-2020</ArticleId><ArticleId IdType="pmc">PMC7236824</ArticleId><ArticleId IdType="pubmed">32398296</ArticleId></ArticleIdList></Reference><Reference><Citation>de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395:1705–14. 10.1016/S0140-6736(20)31030-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31030-8</ArticleId><ArticleId IdType="pmc">PMC7255214</ArticleId><ArticleId IdType="pubmed">32416785</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgi Rossi P, Marino M, Formisano D, et al. Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the province of Reggio Emilia, Italy. MedRxiv. 2020. doi: .10.1101/2020.04.13.20063545</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.13.20063545</ArticleId><ArticleId IdType="pmc">PMC7451640</ArticleId><ArticleId IdType="pubmed">32853230</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Huang F, Xu J, et al. Anti-hypertensive angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. MedRxiv. 2020. 10.1101/2020.03.20.20039586</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.20.20039586</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382(25):2431–40. 10.1056/NEJMoa2006923</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2006923</ArticleId><ArticleId IdType="pmc">PMC7206933</ArticleId><ArticleId IdType="pubmed">32356627</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. 2020 Jun 18;382(25):2441-8. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.10.1056/NEJMoa2008975</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2008975</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2008975</ArticleId><ArticleId IdType="pmc">PMC7206932</ArticleId><ArticleId IdType="pubmed">32356628</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedeschi S, Giannella M, Bartoletti M, Trapani F, Tadolini M, Borghi C, et al. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19. [published online ahead of print, 2020 Apr 27]. Clin Infect Dis. 2020. July 28;71(15):899–901. 10.1093/cid/ciaa492</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa492</ArticleId><ArticleId IdType="pmc">PMC7197592</ArticleId><ArticleId IdType="pubmed">32339215</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco ME, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R, Mascitelli A, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart. 2020;106(19): Published Online: July 1, 2020.10.1136/heartjnl-2020-317336</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2020-317336</ArticleId><ArticleId IdType="pmc">PMC7371482</ArticleId><ArticleId IdType="pubmed">32611676</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes Metab Res Rev. 2020;36:e3319. 10.1002/dmrr.3319</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3319</ArticleId><ArticleId IdType="pmc">PMC7228407</ArticleId><ArticleId IdType="pubmed">32233013</ArticleId></ArticleIdList></Reference><Reference><Citation>Štubljar D, Štefin M, Tacar MP, Cerović O. Grosek ©. Prolonged hospitalization is a risk factor for delirium onset: one-day prevalence study in Slovenian intensive care units. Acta Clin Croat. 2019;58(2):265–73. 10.20471/acc.2019.58.02.09</Citation><ArticleIdList><ArticleId IdType="doi">10.20471/acc.2019.58.02.09</ArticleId><ArticleId IdType="pmc">PMC6884389</ArticleId><ArticleId IdType="pubmed">31819322</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>